<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01381718</url>
  </required_header>
  <id_info>
    <org_study_id>SCUSF 0901</org_study_id>
    <secondary_id>SCUSF-0901</secondary_id>
    <secondary_id>ACCL0922</secondary_id>
    <secondary_id>5U10CA081920-11</secondary_id>
    <nct_id>NCT01381718</nct_id>
  </id_info>
  <brief_title>Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor</brief_title>
  <official_title>A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Modafinil may help improve memory, attention, and fatigue caused by cancer
      treatment.

      PURPOSE: This phase II randomized trial studies how well modafinil works in treating
      children with memory and attention problems caused by cancer treatment for a brain tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine whether a 6-week drug trial of modafinil, compared to placebo, is associated
           with improvement in neurocognitive function as defined by parent report of inattention
           or working memory deficits or by direct assessment of attention, working memory, or
           processing speed in children with cognitive impairment after treatment for a primary
           brain tumor.

      Secondary

        -  Determine whether modafinil, compared to placebo, is associated with improved executive
           function (apart from working memory), as assessed using the BRIEF executive function
           and hippocampal learning and executive function tasks from the CogState battery.

        -  Determine whether modafinil, compared to placebo, is associated with reduced fatigue as
           assessed using the PedsQL Multidimensional Fatigue Scale.

        -  Evaluate the safety of modafinil in this population.

      OUTLINE: This is a multicenter study. Participants are randomized to 1 of 2 treatment arms.

        -  Arm I: Participants receive modafinil orally (PO) once daily (QD) on days 1-42.

        -  Arm II: Participants receive placebo PO QD on days 1-42. Participants complete a
           semi-automated, computerized cognitive-testing system (CogState) designed to assess
           psychomotor, attention/vigilance, memory, and other components of executive function by
           presenting different tasks, each with its own set of rules, at baseline and after
           completion of study therapy. Participants also complete the PedsQL Multidimensional
           Fatigue Scale (Peds QL-MFS).

      Parents or legal guardians complete the PedsQL-MFS, the Conners Parent Reported Scale
      (CPR-3), and the Behavior Rating Inventory of Executive Function (BRIEF) at baseline and
      after completion of study therapy.

      Clinical and/or research staff administer the Systematic Assessment for Treatment Emergency
      Events (SAFTEE), a semi-structured interview designed to elicit adverse events, at baseline
      and periodically during study.

      After completion of study therapy, participants are followed up for 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2011</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Change in age-adjusted scores at week six from baseline in any of the 5 questionnaires</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and toxicity of modafinil</measure>
    <time_frame>30 days post intervention</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improved executive function (apart from working memory) as assessed by BRIEF and CogState</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced fatigue as assessed by PedsQL</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">228</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Cognitive/Functional Effects</condition>
  <condition>Fatigue</condition>
  <condition>Neurotoxicity</condition>
  <condition>Psychosocial Effects of Cancer and Its Treatment</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive modafinil orally (PO) once daily (QD) on days 1-42.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo PO QD on days 1-42.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>modafinil</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Age ≥ 6 years and ≤ 17 years 10 months at the time of study entry (so that
             participants will be &lt; 18 at the 6 week evaluation, which is the upper age limit for
             which the included instruments are valid).

          -  Diagnosis of a primary brain tumor treated with at least one of the following:

               1. neurosurgical resection of the brain tumor;

               2. cranial irradiation; or

               3. any chemotherapy to treat the brain tumor.

          -  Off-treatment and progression-free for at least 12 months and ≤ 84 months. Treatment
             cessation is defined as the final dose of chemotherapy, the last dose (fraction) of
             radiation or date of surgery, whichever occurred last.

          -  Parent/Legal Guardian and child able to read English.

          -  Vision and hearing (eyeglasses and/or hearing aid permissible) sufficient for valid
             test administration and cooperation with examinations.

          -  Availability of a reliable parent or legal guardian who is willing and able to
             complete all of the outcome measures and fulfill the requirements of the study,
             including administration of medications and accompanying the participant to all study
             visits.

          -  Females of childbearing potential must have a negative pregnancy test result and must
             agree to use a medically acceptable method of contraception throughout the entire
             study period and for 30 days after the last dose of study drug.

          -  Childbearing potential is defined as girls who are &gt;Tanner stage 2, except for those
             who have documented pan pituitary insufficiency or other hormonal state incompatible
             with pregnancy.

          -  Urine pregnancy tests are acceptable.

        EXCLUSION CRITERIA:

          -  Off treatment &gt; 84 months

          -  Inability to perform the testing procedure (for example, because of aphasia, motor
             deficits affecting the dominant hand, or IQ &lt; 70)

          -  Known cardiac disorders including arrhythmias, hypertension requiring treatment or
             structural heart disease

          -  Diagnosis of narcolepsy, sick sinus syndrome, arrhythmia or prolonged QTc

          -  History of stroke or head injury associated with loss of consciousness within 12
             months of registration

          -  History of grade 2 depression or anxiety or treatment with antidepressants,
             antipsychotics or MAO inhibitors within 30 days of registration

          -  Concurrent treatment with any medications or substances that are potent inhibitors or
             inducers of CYP3A4, hepatic enzyme inducing antiepileptic drugs (EIAEDs),or other
             drugs known to affect the metabolism of modafinil. Examples include but are not
             limited to itraconazole, ketoconazole, doxycycline, rifampin, St. John's wort,
             phenytoin, phenobarbital, diazepam, tricyclic antidepressants.

          -  If patients were previously taking, EIAEDs, they must be off for &gt; 2 weeks prior to
             study enrollment.

          -  Treatment with other stimulant medications within 14 days of registration; however, a
             diagnosis of ADHD does NOT exclude a child from participation

          -  Participants with known hypersensitivity to modafinil, armodafinil or any of its
             components
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey P. Krischer, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicole J. Ullrich, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital Boston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>April Peterson, BS</last_name>
      <phone>205-939-5854</phone>
    </contact>
    <investigator>
      <last_name>Alyssa Reddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Reichman</last_name>
      <phone>323-361-5973</phone>
    </contact>
    <investigator>
      <last_name>David R Freyer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Lew</last_name>
      <phone>650-725-4318</phone>
    </contact>
    <investigator>
      <last_name>Neyssa Marina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis Aguilling</last_name>
      <phone>415-502-4372</phone>
    </contact>
    <investigator>
      <last_name>Robert Goldsby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Colorado; Saint Joseph Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Madden, RN MSN CPNP</last_name>
      <phone>720-777-3407</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Arens, CCRP</last_name>
      <phone>860-545-9614</phone>
    </contact>
    <investigator>
      <last_name>Michael Isakoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Children's National Medical Center</last_name>
      <phone>202-884-2549</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Garber, RN</last_name>
      <phone>321-841-3837</phone>
    </contact>
    <investigator>
      <last_name>Don Eslin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic- Pensacola</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Ingram, RN BSN</last_name>
      <phone>904-697-3985</phone>
    </contact>
    <investigator>
      <last_name>Scott Bradfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Flanary, RN BSN</last_name>
      <phone>727-767-6466</phone>
    </contact>
    <investigator>
      <last_name>Gregory Hale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SunCoast CCOP Research Base at the University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey P. Krischer, MD, PhD</last_name>
      <phone>813-979-6706</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Griffin</last_name>
      <phone>404-785-0653</phone>
    </contact>
    <investigator>
      <last_name>Tobey MacDonald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emelie Chang, CCRA</last_name>
      <phone>808-586-2979</phone>
    </contact>
    <investigator>
      <last_name>Robert Wilkinson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johnathan Davidson</last_name>
      <phone>312-355-2936</phone>
    </contact>
    <investigator>
      <last_name>Mary Lou Schmidt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children- Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46163</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Claussen</last_name>
      <phone>317-944-2839</phone>
    </contact>
    <investigator>
      <last_name>Robert Fallon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kosair Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belinda Coy</last_name>
      <phone>502-852-2915</phone>
    </contact>
    <investigator>
      <last_name>Kanyalakshimi Ayyanar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Children's Hospital Boston</last_name>
      <phone>800-828-6622</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CS Mott/University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Satarino</last_name>
      <phone>734-763-6344</phone>
    </contact>
    <investigator>
      <last_name>Rama Jasty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Bell</last_name>
      <phone>507-284-8871</phone>
    </contact>
    <investigator>
      <last_name>Amulya NageswaraRao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Cole, RN CPON</last_name>
      <phone>601-984-2712</phone>
    </contact>
    <investigator>
      <last_name>Gail Megason, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital and Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris Laurence</last_name>
      <phone>816-234-3878</phone>
    </contact>
    <investigator>
      <last_name>Maxine Hetherington, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Saint Louis University Cancer Center</last_name>
      <phone>314-977-4440</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Eisenberg, CCRP</last_name>
      <phone>505-272-5980</phone>
    </contact>
    <investigator>
      <last_name>Koh Boayue, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Herbert Irving Comprehensive Cancer C</last_name>
      <phone>212-305-8615</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Cavallerano, CCRP</last_name>
      <phone>315-464-7601</phone>
    </contact>
    <investigator>
      <last_name>Karol Kerr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Gonzalez, CCRP</last_name>
      <phone>405-271-4412</phone>
      <phone_ext>42551</phone_ext>
    </contact>
    <investigator>
      <last_name>Rene McNail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Doernbecher Children's Hospital/ Oregoon Health Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kitt Swartz</last_name>
      <phone>503-494-0200</phone>
    </contact>
    <investigator>
      <last_name>Kellie Nazemi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Armstrong, PhD</last_name>
      <phone>215-590-1709</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>East Tennessee Children's Hospital</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Bush, RN</last_name>
      <phone>865-541-8617</phone>
    </contact>
    <investigator>
      <last_name>Ray C Pais, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annemarie McClennan, MS CCRA</last_name>
      <phone>901-595-2734</phone>
    </contact>
    <investigator>
      <last_name>Amar Gajjar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Children's Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Edens, CCRP</last_name>
      <phone>615-936-1762</phone>
    </contact>
    <investigator>
      <last_name>Adam Esbenshade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Driscoll Children's Hospital</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Hollek</last_name>
      <phone>361-694-4439</phone>
    </contact>
    <investigator>
      <last_name>Cris Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Simmons Comprehensive Cancer Center a</last_name>
      <phone>866-460-4673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3900</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leanne Embry, PhD</last_name>
      <phone>210-704-2987</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jolene Cheslock</last_name>
      <phone>920-433-8272</phone>
    </contact>
    <investigator>
      <last_name>John Hill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>http://cancer.gov/clinicaltrials/SCUSF-0901</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQ® database</description>
  </link>
  <verification_date>September 2011</verification_date>
  <lastchanged_date>May 20, 2013</lastchanged_date>
  <firstreceived_date>June 23, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>childhood brain tumor</keyword>
  <keyword>neurotoxicity</keyword>
  <keyword>fatigue</keyword>
  <keyword>cognitive/functional effects</keyword>
  <keyword>psychosocial effects of cancer and its treatment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
